VLM Multi-Model Comparison Report

Dataset: progression_recurrence_survival_1yr_2yr_3yr_4yr_5yr_v1_1

Subtask: died_of_cancer_1_yr

Question:

Based on the provided medical history and cancer evidence, is cancer-related mortality expected within 1 year of treatment initiation?

Correct Answer: No

Model: OpenGVLab/InternVL3_5-8B

middle image from each view: **[CORRECT]** <think> The patient has been diagnosed with a T1N1M0 lung adenocarcinoma, which is a stage IB cancer. The treatment plan involves lobectomy, and if the tumor is stage IB or II, adjuvant chemotherapy will be needed. The patient's overall health appears stable, with no significant comorbidities that would affect treatment outcomes. The absence of metastatic disease (M0) and the localized nature of the tumor (T1N1) suggest a favorable prognosis. Given the stage and treatment plan, cancer-related mortality within 1 year of treatment initiation is not expected. </think> <brief reasoning trace with explanation for answer selection> The patient has a stage IB lung adenocarcinoma (T1N1M0) with a treatment plan involving lobectomy and possible adjuvant chemotherapy. The absence of metastatic disease and the localized nature of the tumor suggest a favorable prognosis. The patient's overall health is stable, with no significant comorbidities affecting treatment outcomes. Therefore, cancer-related mortality within 1 year of treatment initiation is not expected. | <answer>No</answer>

middle axial image: **[CORRECT]** <think> The patient has been diagnosed with a T1N1M0 lung adenocarcinoma, which is a stage IB cancer. The treatment plan involves lobectomy, and if the tumor is stage IB or II, adjuvant chemotherapy will be required. Stage IB tumors generally have a good prognosis with appropriate treatment, and the patient is expected to undergo surgery without immediate need for chemotherapy if the tumor is indeed stage I. The patient's overall health appears stable, with no significant comorbidities that would adversely affect treatment outcomes. Given the stage and treatment plan, cancer-related mortality within 1 year of treatment initiation is not expected. </think> <brief reasoning trace with explanation for answer selection> The patient has a T1N1M0 lung adenocarcinoma, classified as stage IB. The treatment plan includes lobectomy, with adjuvant chemotherapy only if the tumor is stage IB or II. Stage IB tumors generally have a good prognosis with appropriate treatment. The patient's overall health is stable, and there are no significant comorbidities affecting treatment outcomes. Therefore, cancer-related mortality within 1 year of treatment initiation is not expected. | <answer>No</answer>

no image: [INCORRECT] <think> The patient is a 61-year-old female diagnosed with a 2.2 cm left lower lobe pulmonary nodule, confirmed as adenocarcinoma. The imaging studies, including PET-CT, show no evidence of metastatic disease, indicating a localized tumor. The AJCC staging indicates a T1N1M0 stage, suggesting a stage IB cancer. The treatment plan involves lobectomy, and if the tumor is stage I without nodal involvement, adjuvant chemotherapy is not required. Given the early stage and the planned surgical intervention, cancer-related mortality within 1 year of treatment initiation is not expected. </think> <brief reasoning trace with explanation for answer selection> | <answer> The patient has a T1N1M0 stage lung adenocarcinoma with no evidence of metastatic disease. The treatment plan includes lobectomy, and if the tumor is stage I without nodal involvement, adjuvant chemotherapy is not required. Given the early stage and planned surgical intervention, cancer-related mortality within 1 year of treatment initiation is not expected. </answer>

no radiology report: [INCORRECT] <think> The timeline indicates a diagnosis of a malignant neoplasm of the bronchus and lung, staged as T1 N1 M0, which is Stage IIIA according to the 7th AJCC edition. This stage suggests a localized but advanced cancer with regional lymph node involvement. The treatment plan appears to involve imaging and possibly chemotherapy or other oncological treatments. Given the stage and typical prognosis for such cancers, there is a significant risk of mortality within a year without effective treatment. The presence of multiple nodules and the patient's overall health metrics (e.g., BMI, blood pressure) also suggest a complex clinical picture that may not respond well to treatment, increasing the likelihood of cancer-related mortality within a year. </think> <brief reasoning trace with explanation for answer selection> The patient has a Stage IIIA malignant neoplasm of the bronchus and lung, indicating a significant risk of mortality within a year due to the advanced stage and regional lymph node involvement. The treatment complexity and the patient's health metrics further support a higher risk of cancer-related mortality. | <answer>Yes</answer>

100 axial images (no timeline): [CORRECT] <brief reasoning trace with explanation for answer selection> | <answer></answer> The provided PATIENT_TIMELINE does not include any specific medical history, cancer evidence, imaging, pathology, or treatment details. Without explicit evidence regarding the presence of cancer, its stage, or treatment outcomes, it is not possible to determine the likelihood of cancer-related mortality within 1 year of treatment initiation. | <answer>No</answer>

Model: OctoMed/OctoMed-7B

middle image from each view: [CORRECT] <think>First, I need to determine whether the patient's cancer-related mortality is expected within one year of treatment initiation based on the provided medical history and imaging findings. The patient is a 61-year-old female diagnosed with left lower lobe adenocarcinoma of the lung. The tumor is T1N0M0 (no nodal involvement or metastasis evident on imaging). She has undergone a PET-CT showing no metastatic disease, and the biopsy confirmed adenocarcinoma. She is scheduled for lobectomy, which is standard for early-stage lung cancer. Key factors to consider for prognosis and mortality risk: - Stage: T1N0M0, which is early stage. - No evidence of nodal involvement or distant metastasis. - She is undergoing surgery, which is curative intent. - No mention of high-risk features such as large tumor size, lymphovascular invasion, or positive margins. - She has a history of DCIS and breast cancer, but no recurrence. - She is on menopausal hormone therapy, but this is not directly related to lung cancer prognosis. - No significant comorbidities mentioned that would drastically affect survival. - The imaging shows no suspicious lymph nodes or metastases. - The PET-CT showed no significant FDG uptake outside the primary tumor, indicating no active metastatic disease. - The patient is active and has no significant symptoms like weight loss or night sweats. - The tumor is localized and resectable. Given these factors, the prognosis is generally favorable for early-stage lung adenocarcinoma treated with surgery. The absence of nodal involvement or metastasis suggests a low risk of mortality within the first year. The main

treatment is surgery, and adjuvant therapy decisions will depend on final pathology, but the current data do not indicate high-risk features that would suggest imminent mortality. Therefore, based on the provided information, there is no evidence to suggest cancer-related mortality within the first year.</think> <answer>No</answer>

middle axial image: **[CORRECT]** <think>First, I need to determine whether the patient's cancer-related mortality is expected within one year of treatment initiation based on the provided timeline and medical records. The patient is a 61-year-old female diagnosed with left lower lobe adenocarcinoma of the lung. The tumor is T1N0M0 (no nodal involvement or metastasis evident on imaging). She underwent a PET-CT which showed no metastatic disease, and the biopsy confirmed adenocarcinoma. She has a history of DCIS treated with lumpectomy and tamoxifen, and currently is on menopausal hormone therapy. Key factors to consider for prognosis and mortality risk include: - Tumor stage: T1N0M0 suggests early-stage lung cancer. - No evidence of nodal involvement or distant metastasis. - She is undergoing lobectomy as planned, which is standard for early-stage lung cancer. - No mention of high-risk features such as positive margins, lymphovascular invasion, or poor differentiation. - She has comorbidities including asthma, hypothyroidism, and a history of smoking, but these do not directly indicate poor prognosis for the lung cancer. - The patient is active and has no significant symptoms like weight loss or night sweats, which would suggest more aggressive disease. - The PET-CT showed no FDG avidity outside the primary tumor, indicating no aggressive metastatic spread. - The bone density and other lab values do not indicate significant frailty or other factors that would impact survival. - The treatment plan includes lobectomy and possibly mediastinal node sampling, which aligns with standard care for early-stage lung cancer. - The patient is being followed closely with imaging and has no evidence of progression. Given the early stage, absence of nodal or metastatic disease, and standard treatment plan, the likelihood of cancer-related mortality within one year is low. The patient's overall health status and the tumor characteristics do not suggest a high risk of mortality within the first year. Therefore, based on the provided information, the answer is "No."</think> <answer>No</answer>

no image: **[CORRECT]** <think>First, I need to determine whether the patient's cancer-related mortality is expected within one year of treatment initiation based on the provided timeline and medical records. The key factors to consider include the cancer stage, tumor biology, treatment intent, completeness, surgical margins, nodal status, biomarkers, and any other relevant clinical data. Looking at the patient's history, she was diagnosed with a 2.2 cm left lower lobe adenocarcinoma of the lung. The PET-CT showed no evidence of metastasis, and the MRI brain also showed no metastatic disease. The tumor is described as T1 (based on imaging), which typically indicates a localized tumor without lymph node involvement. The patient underwent a CT-guided FNA and core biopsy, which confirmed adenocarcinoma. The biopsy report mentions TTF-1 negative but BRST-2 negative and napsin A scattered positive, which aligns with lung adenocarcinoma. The patient's treatment plan includes lobectomy, as indicated by the tumor board discussion. The tumor abuts the fissure but no fissure nodularity or satellite nodules were noted. The patient has no significant nodal involvement on imaging, and the PET-CT did not show any hypermetabolic activity outside the primary lesion. This suggests that the cancer is localized, which is a favorable prognostic factor. The patient's overall health status is good, with no significant comorbidities that would contraindicate surgery. She is active, with a BMI of 26.5 and a body surface area of 1.74 m^2, which are within acceptable ranges for surgery. The planned treatment is lobectomy, which is standard for early-stage lung cancer. Given that the tumor is T1N0M0 (based on the information provided), the prognosis is generally favorable. The absence of nodal involvement and distant metastasis, along with the patient's good performance status, supports a low risk of cancer-related mortality within the first year. The main concern would be recurrence, but with appropriate surgical resection and follow-up, the likelihood of mortality within one year is low. Therefore, based on the provided data, the answer is that cancer-related mortality is not expected within one year of treatment initiation.</think> <brief reasoning trace with explanation for answer selection> | <answer>No</answer>

no radiology report: [CORRECT] <think>First, I carefully reviewed the provided patient timeline and medical records. The timeline includes multiple dates of imaging and clinical interventions, but no specific mention of cancer-related mortality or survival data. The records show a patient with a history of malignant neoplasm of the bronchus and lung, but no direct evidence or documentation of cancer-related death within one year of treatment initiation is present. The imaging studies and clinical notes focus on treatment monitoring, complications, and follow-up rather than mortality outcomes. Without explicit documentation of cancer-related death within one year, I cannot conclude that cancer-related mortality is expected within that timeframe. Therefore, the correct answer is "No."</think> <answer>No</answer>

100 axial images (no timeline): [CORRECT] <think>To determine whether cancer-related mortality is expected within 1 year of treatment initiation, I must analyze the provided patient timeline. The timeline only includes the date of birth and ethnicity/race information, but no clinical details such as cancer diagnosis, stage, treatment type, or outcomes. Without this critical data, it is impossible to assess the risk of cancer-related mortality. The timeline lacks any evidence of cancer treatment initiation, progression, or survival data. Therefore, I cannot conclude whether cancer-related mortality is expected within 1 year of treatment initiation based solely on the provided information.</think> <answer>No</answer>

Model: Qwen/Qwen3-VL-8B-Instruct

middle image from each view: [CORRECT] The patient was diagnosed with stage I lung adenocarcinoma in April 2013. The PET-CT and CT scans confirmed a 2.2 cm left lower lobe nodule with no evidence of metastatic disease. The tumor board unanimously decided to proceed with a lobectomy. The patient is described as "extremely active" and able to do the StairMaster for 20 minutes. There is no evidence of metastasis, and the patient is not a candidate for adjuvant chemotherapy. The timeline shows that treatment initiation (lobectomy) occurred in May 2013, and the patient's prognosis is favorable for stage I disease. Therefore, cancer-related mortality is not expected within 1 year of treatment initiation. No

middle axial image: [CORRECT] The provided PATIENT_TIMELINE documents a 61-year-old female diagnosed with stage I lung adenocarcinoma (T1N0M0) in April 2013. The timeline includes multiple imaging studies (chest X-ray, CT, PET-CT, MRI brain) that confirmed the primary tumor and ruled out metastatic disease. The tumor was staged as T1N0M0, and the treatment plan, discussed at tumor board on 05/22/2013, was to proceed with lobectomy. The note explicitly states that if the tumor is a stage I tumor without nodal involvement, adjuvant chemotherapy is not needed. The patient is described as "extremely active" and "in no acute distress" with no significant comorbidities impacting prognosis. The timeline does not contain any evidence of disease progression, recurrence, or treatment failure within the 1-year window. Therefore, based on the evidence of early-stage disease with planned curative surgery and no signs of metastasis or progression, cancer-related mortality is not expected within 1 year of treatment initiation. No | No

no image: [CORRECT] <brief reasoning trace with explanation for answer selection> | <answer></answer> The patient was diagnosed with stage I lung adenocarcinoma (T1N0M0) based on imaging and biopsy results, with no evidence of metastasis. The tumor was localized and resectable. The timeline shows that treatment (lobectomy) was planned and discussed at tumor board on 05/22/2013, and the patient was counseled and prepared for surgery. There is no evidence of advanced disease, systemic symptoms, or rapid progression. The patient’s performance status is good (active, able to exercise), and no treatment-related mortality is indicated in the timeline. Therefore, cancer-related mortality within 1 year of treatment initiation is not expected. <answer>No</answer>

no radiology report: [CORRECT] The patient's medical timeline indicates a diagnosis of malignant neoplasm of the bronchus and lung (ICD9CM/162.9) in April 2013, with a subsequent

clinical staging of cT1N1M0 (AJCC 7th Edition) on May 2, 2013. This staging corresponds to Stage II (T1N1M0) lung cancer. The timeline includes imaging (CT chest, PET-CT) and clinical assessments, but there is no evidence of treatment initiation or any documentation of survival status beyond the timeline provided. The question asks whether cancer-related mortality is expected within 1 year of treatment initiation. Since the timeline does not provide information on treatment initiation or patient survival, it is impossible to determine if cancer-related mortality is expected within 1 year. The provided evidence does not support a definitive "Yes" or "No" answer. <brief reasoning trace with explanation for answer selection> | <answer></answer> The provided PATIENT_TIMELINE documents a diagnosis of malignant neoplasm of the bronchus and lung (ICD9CM/162.9) and a clinical staging of cT1N1M0 (Stage II) on May 2, 2013. However, the timeline does not contain any information regarding the initiation of treatment, the patient's response to treatment, or any documented survival outcomes. Without evidence of treatment initiation or survival data, it is impossible to determine if cancer-related mortality is expected within 1 year. Therefore, the correct answer is "No" because the evidence does not support the expectation of mortality within the specified timeframe. <answer>No</answer>

100 axial images (no timeline): **[CORRECT]** The provided PATIENT_TIMELINE contains no information regarding any cancer diagnosis, treatment, or related clinical findings. There are no entries describing tumors, imaging results, pathology reports, or any oncological events. Without any evidence of cancer or its progression, it is impossible to determine cancer-related mortality risk. <brief reasoning trace with explanation for answer selection> | <answer>No</answer>

Model: google/medgemma-1.5-4b-it

middle image from each view: **[CORRECT]** <unused94>thought The user wants me to determine if cancer-related mortality is expected within 1 year based on the provided patient timeline. 1. **Identify the core question:** Is cancer-related mortality expected within 1 year? 2. **Scan the timeline for cancer diagnosis and treatment:** * April 2013: Diagnosis of adenocarcinoma of the lung (left lower lobe). * May 2013: CT-guided FNA and core biopsy confirms adenocarcinoma. * May 15, 2013: MRI brain shows no evidence of metastatic disease. * May 16, 2013: PET-CT shows a 2.2 cm left lower lobe pulmonary nodule (consistent with the biopsy finding) but no evidence of metastasis. * May 2013: Tumor board discussion recommends lobectomy. * May 2013: Patient undergoes lobectomy. * May 2013: Pathology confirms adenocarcinoma. 3. **Assess the stage and treatment:** * The tumor is described as T1 (based on the clinical notes, although not explicitly stated as T1 in the initial diagnosis, the subsequent discussion and treatment plan suggest it's likely early stage). * The patient underwent surgery (lobectomy). * There is no mention of adjuvant chemotherapy or other treatments. * The PET-CT showed no evidence of metastasis. 4. **Evaluate the risk of mortality:** * For early-stage (T1) lung cancer, especially after surgical resection, the prognosis is generally good. * The absence of metastasis on PET-CT is a strong indicator of favorable prognosis. * The patient is 61 years old, which is not extremely advanced age. * There is no mention of other significant comorbidities that would drastically worsen prognosis. 5. **Formulate the answer:** Based on the diagnosis of early-stage lung cancer (T1) and successful surgical resection with no evidence of metastasis, the risk of cancer-related mortality within 1 year is low. 6. **Select the correct option:** "No". 7. **Construct the reasoning:** The patient was diagnosed with T1 lung adenocarcinoma in April 2013. A lobectomy was performed in May 2013. Subsequent imaging (PET-CT) showed no evidence of metastasis. For early-stage lung cancer treated surgically, the prognosis is generally favorable, and the risk of mortality within one year is low.<unused95><brief reasoning trace with explanation for answer selection>The patient was diagnosed with T1 lung adenocarcinoma in April 2013. A lobectomy was performed in May 2013. Subsequent imaging (PET-CT) showed no evidence of metastasis.

For early-stage lung cancer treated surgically, the prognosis is generally favorable, and the risk of mortality within one year is low. <answer>No</answer>

middle axial image: [CORRECT] <unused94>thought The user wants me to determine if cancer-related mortality is expected within 1 year based on the provided patient timeline. 1. **Identify the core question:** Is cancer-related mortality expected within 1 year? 2. **Scan the timeline for cancer diagnosis and treatment:** * April 2013: Diagnosis of adenocarcinoma of the lung (left lower lobe). * May 2013: CT-guided FNA and core biopsy confirms adenocarcinoma. * May 15, 2013: MRI brain shows no evidence of metastatic disease. * May 16, 2013: PET-CT shows a 2.2 cm left lower lobe pulmonary nodule (consistent with the biopsy finding) but no evidence of metastasis. * May 2013: Tumor board discussion recommends lobectomy. * May 2013: Patient undergoes lobectomy. * May 2013: Pathology report confirms adenocarcinoma. 3. **Assess the stage and treatment:** * The tumor is described as T1 (based on the clinical notes and staging codes). * The patient underwent surgery (lobectomy). * There is no mention of adjuvant chemotherapy or other treatments. * The PET-CT showed no evidence of metastasis (N0, M0). 4. **Evaluate the risk of mortality:** * A T1 lung cancer, especially one that has been surgically removed with no evidence of metastasis, has a very low risk of dying from the cancer within the first year. * The patient is 61 years old, which is not extremely advanced age, but the cancer itself is the primary factor. * The patient is currently undergoing follow-up care (pulmonary function test). 5. **Formulate the answer:** Based on the diagnosis of T1 lung cancer and successful surgical removal with no evidence of metastasis, the risk of cancer-related mortality within 1 year is very low. 6. **Select the correct option:** "No". 7. **Construct the reasoning:** The patient was diagnosed with T1 lung adenocarcinoma in April 2013. A CT-guided biopsy confirmed the diagnosis. A PET-CT scan in May 2013 showed the tumor but no evidence of metastasis. The patient underwent a lobectomy in May 2013. Pathology confirmed adenocarcinoma. There is no mention of adjuvant therapy or recurrence. A T1 lung cancer with no metastasis has a very low risk of mortality within one year. Therefore, cancer-related mortality is not expected within 1 year.<unused95><brief reasoning trace with explanation for answer selection> The patient was diagnosed with T1 lung adenocarcinoma in April 2013. A CT-guided biopsy confirmed the diagnosis. A PET-CT scan in May 2013 showed the tumor but no evidence of metastasis. The patient underwent a lobectomy in May 2013. Pathology confirmed adenocarcinoma. There is no mention of adjuvant therapy or recurrence. A T1 lung cancer with no metastasis has a very low risk of mortality within one year. Therefore, cancer-related mortality is not expected within 1 year. <answer>No</answer>

no image: [INCORRECT] <brief reasoning trace with explanation for answer selection> | <answer></answer> The patient has a history of lung adenocarcinoma diagnosed in April 2013. The patient has undergone several imaging studies including a PET-CT and a CT chest scan. The PET-CT scan from May 16, 2013, showed a 2.2 cm left lower lobe pulmonary nodule with an SUVmax of 4.9, consistent with malignancy. The CT chest scan from April 27, 2013, also showed a 2 x 2.1-cm masslike opacity with spiculated margins in the left lower lobe. The patient has also undergone a biopsy of the lung nodule, which confirmed the diagnosis of adenocarcinoma. The patient has received treatment for this cancer, including surgery (lobectomy) and chemotherapy. The patient's clinical status is currently stable, and there is no mention of recurrence or progression of the cancer in the provided timeline. Therefore, based on the information available, cancer-related mortality within 1 year of treatment initiation is not expected. No | Yes

no radiology report: [INCORRECT] The patient has a history of malignant neoplasm of bronchus and lung, unspecified, diagnosed in 2013. The patient has undergone multiple imaging studies including CT chest and PET scan, as well as a chest tube placement and removal. The patient has also had spirometry and bronchodilation responsiveness testing. The patient's current status is not explicitly stated, but the presence of a malignancy, even if treated, carries a risk of recurrence or progression. The patient's BMI is 26.5, which is overweight. The patient has a history of asthma. The patient has had multiple procedures and tests. The patient

has had multiple visits to the oncology clinic. The patient has had multiple visits to the outpatient clinic. The patient has had multiple visits to the radiology department. The patient has had multiple visits to the pulmonary function lab. The patient has had multiple visits to the clinic. The patient has

100 axial images (no timeline): **[INCORRECT]** FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |

```
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_
```

Model: google/medgemma-4b-it

middle image from each view: **[CORRECT]** No

middle axial image: **[CORRECT]** No

no image: **[CORRECT]** No

no radiology report: **[CORRECT]** No

100 axial images (no timeline): **[CORRECT]** The images show a well-defined, homogeneous mass within the breast tissue. The presence of a mass and the lack of any mention of metastasis or other concerning findings suggests a localized, potentially treatable cancer. Given the absence of evidence of advanced disease, cancer-related mortality within one year is not expected. No

Subtask: died_of_cancer_2_yr

Question:

Based on the provided medical history and cancer evidence, is cancer-related mortality expected within 2 years of treatment initiation?

Correct Answer: No

Model: OpenGVLab/InternVL3_5-8B

middle image from each view: **[CORRECT]** <think> The patient was diagnosed with a T1N1M0 lung adenocarcinoma, which is a stage IB cancer. The treatment plan included lobectomy, and if the tumor is stage IB or II, adjuvant chemotherapy would be needed. The patient's overall health appears stable, with no significant comorbidities that would affect treatment outcomes. Given the stage and treatment plan, cancer-related mortality within 2 years of treatment initiation is not expected. </think> <brief reasoning trace with explanation for answer selection> The patient was diagnosed with a T1N1M0 lung adenocarcinoma, which is a stage IB cancer. The treatment plan included lobectomy, and if the tumor is stage IB or II, adjuvant chemotherapy would be needed. The patient's overall health appears stable, with no significant comorbidities that would affect treatment outcomes. Given the stage and treatment plan, cancer-related mortality within 2 years of treatment initiation is not expected. | <answer>No</answer>

middle axial image: **[CORRECT]** <think> The patient has been diagnosed with a T1N1M0 lung adenocarcinoma, which is a stage IB cancer. The treatment plan involves lobectomy, and if the tumor is stage IB or II, adjuvant chemotherapy will be needed. Stage IB tumors generally have a good prognosis with appropriate treatment, and the five-year survival rate is typically high. There is no indication of metastatic disease (M0), and the patient's overall health appears stable. The patient's age and other comorbidities (like asthma) are managed, and there is no evidence of significant complications that would adversely affect outcomes. Given the stage and treatment plan, cancer-related mortality within 2 years of treatment initiation is not expected. </think> <brief reasoning trace with explanation for answer selection> The patient has a stage IB lung adenocarcinoma (T1N1M0) with a treatment plan involving lobectomy and possible adjuvant chemotherapy if needed. Stage IB tumors generally have a good prognosis with appropriate treatment, and there is no evidence of metastatic disease. The patient's overall health appears stable, and there are no significant comorbidities that would adversely affect outcomes. Therefore, cancer-related mortality within 2 years of treatment initiation is not expected. | <answer>No</answer>

no image: **[CORRECT]** <think> The patient is a 61-year-old female diagnosed with a 2.2 cm left lower lobe pulmonary nodule, confirmed as adenocarcinoma. The imaging studies, including PET-CT, show no evidence of metastatic disease, indicating a localized tumor. The AJCC staging is T1N1M0, suggesting a stage IB cancer. The treatment plan involves lobectomy, and if the tumor is stage I without nodal involvement, adjuvant chemotherapy is not required. Given the early stage and appropriate treatment, cancer-related mortality within 2 years of treatment initiation is not expected. </think> <brief reasoning trace with explanation for answer selection> The patient has a T1N1M0 stage lung adenocarcinoma with no metastatic disease. The treatment plan includes lobectomy, and if the tumor is stage I without nodal involvement, adjuvant chemotherapy is not required. Given the early stage and appropriate treatment, cancer-related mortality within 2 years is not expected. | <answer>No</answer>

no radiology report: [INCORRECT] <think> The timeline indicates a diagnosis of a malignant neoplasm of the bronchus and lung, staged as T1 N1 M0, which is Stage IIIA according to the 7th AJCC edition. This stage suggests a localized but advanced cancer with regional lymph node involvement. The treatment plan likely involves a combination of surgery, chemotherapy, and/or radiation therapy. Given the stage and typical prognosis for such cancers, there is a significant risk of cancer-related mortality within 2 years of treatment initiation. The presence of multiple nodules and the need for PET/CT imaging also suggest a more aggressive disease course. </think> <brief reasoning trace with explanation for answer selection> The patient has a Stage IIIA malignant neoplasm of the bronchus and lung, indicating a significant risk of cancer-related mortality within 2 years due to the advanced stage and regional lymph node involvement. | <answer>Yes</answer>

100 axial images (no timeline): [CORRECT] <brief reasoning trace with explanation for answer selection> | <answer></answer> The provided PATIENT_TIMELINE does not include any specific medical history, cancer evidence, imaging, pathology, or treatment details. Without explicit evidence regarding the presence of cancer, its stage, or treatment outcomes, it is not possible to determine the likelihood of cancer-related mortality within 2 years of treatment initiation. | <answer>No</answer>

Model: Qwen/Qwen3-VL-8B-Instruct

middle image from each view: [CORRECT] The patient was diagnosed with stage I lung adenocarcinoma in April 2013. The timeline shows that a tumor board meeting occurred on May 22, 2013, and the unanimous decision was to proceed with a lobectomy. The patient's clinical status at the time of diagnosis was described as "well-appearing" with no significant symptoms beyond anxiety. The imaging (PET-CT, MRI brain, CT chest) confirmed a localized tumor with no evidence of metastasis. The treatment plan was surgical resection, with adjuvant chemotherapy only if the tumor was found to be stage IB or II. Given the stage I diagnosis and the planned curative surgical intervention, cancer-related mortality within 2 years of treatment initiation is not expected. <brief reasoning trace with explanation for answer selection> | <answer></answer> No

middle axial image: [CORRECT] The provided PATIENT_TIMELINE documents a 61-year-old female diagnosed with stage I lung adenocarcinoma (T1N0M0) in April 2013. The timeline includes multiple imaging studies (CT, PET-CT, MRI) that confirmed the primary tumor and ruled out metastatic disease. The treatment plan, discussed at tumor board on 05/22/2013, was to proceed with lobectomy. The note from 05/17/2013 explicitly states that if the tumor is a stage I tumor without nodal involvement, adjuvant chemotherapy is not needed. The patient is described as "extremely active" and "able to do the StairMaster for 20 minutes," indicating good functional status. There is no evidence of metastasis, and the tumor is localized. The timeline does not contain any information about the patient's death or any events indicating cancer-related mortality within 2 years of treatment initiation. Therefore, based on the evidence provided, cancer-related mortality is not expected within 2 years of treatment initiation. <brief reasoning trace with explanation for answer selection> | <answer></answer> No

no image: [CORRECT] <brief reasoning trace with explanation for answer selection> | <answer></answer> The patient was diagnosed with stage I lung adenocarcinoma (T1N0M0) based on imaging and biopsy results, with no evidence of metastasis. The tumor was localized and resectable, and the tumor board unanimously decided to proceed with lobectomy. The patient is otherwise healthy, with no significant comorbidities or symptoms, and is highly active. There is no evidence of advanced disease, and adjuvant chemotherapy is not indicated for stage I. Given the early stage, localized disease, and planned curative surgery, cancer-related mortality within 2 years is not expected. <answer>No</answer>

no radiology report: [CORRECT] The patient's medical timeline indicates a diagnosis of malignant neoplasm of the bronchus and lung (ICD9CM/162.9) in April 2013, with a clinical staging of cT1N1M0 (AJCC 7th Edition) on May 2, 2013. This is a stage IIIA lung cancer. The timeline includes imaging (CT chest, PET-CT) and a case management visit, suggesting active oncology care. However, the timeline does not contain any information about the initiation of treatment, the specific treatment modality, its response, or any documented survival data. Without evidence of treatment initiation or its effectiveness, it is impossible to determine if cancer-related mortality is expected within 2 years. The question requires evidence from the timeline, which is absent. No

100 axial images (no timeline): [CORRECT] The provided PATIENT_TIMELINE contains no information regarding any cancer diagnosis, treatment, or related clinical findings. There are no entries describing tumors, imaging results, pathology reports, or any oncological history. Without any evidence of cancer or its progression, it is impossible to determine whether cancer-related mortality is expected within 2 years of treatment initiation. <brief reasoning trace with explanation for answer selection> | <answer>No</answer>

Subtask: died_of_cancer_3_yr

Question:

Based on the provided medical history and cancer evidence, is cancer-related mortality expected within 3 years of treatment initiation?

Correct Answer: No

Model: OpenGVLab/InternVL3_5-8B

middle image from each view: **[CORRECT]** <think> The patient was diagnosed with a T1N1M0 lung adenocarcinoma, which is a stage IB cancer. The treatment plan included lobectomy, and if the tumor is stage IB or II, adjuvant chemotherapy would be needed. The patient's overall health appears stable, with no significant comorbidities that would affect treatment outcomes. Given the stage and treatment plan, cancer-related mortality within 3 years of treatment initiation is not expected. </think> <brief reasoning trace with explanation for answer selection> The patient was diagnosed with a T1N1M0 lung adenocarcinoma, which is a stage IB cancer. The treatment plan included lobectomy, and if the tumor is stage IB or II, adjuvant chemotherapy would be needed. The patient's overall health appears stable, with no significant comorbidities that would affect treatment outcomes. Given the stage and treatment plan, cancer-related mortality within 3 years of treatment initiation is not expected. | <answer>No</answer>

middle axial image: **[CORRECT]** <think> The patient has been diagnosed with a T1N1M0 lung adenocarcinoma, which is a stage IB cancer. According to the AJCC 7th edition staging, stage IB tumors have a 5-year survival rate of approximately 70-80%. The patient is planned for lobectomy, which is the standard treatment for stage IB lung cancer. The absence of metastatic disease (M0) and the localized nature of the tumor (T1N1) suggest a favorable prognosis. The patient's overall health appears stable, with no significant comorbidities that would adversely affect treatment outcomes. Given the stage and treatment plan, cancer-related mortality within 3 years is not expected. </think> <brief reasoning trace with explanation for answer selection> The patient has a stage IB lung adenocarcinoma (T1N1M0) with no evidence of metastasis. The treatment plan includes lobectomy, which is effective for localized tumors. The 5-year survival rate for stage IB is high, and there are no significant comorbidities affecting prognosis. | <answer>No</answer>

no image: **[CORRECT]** <think> The patient is a 61-year-old female diagnosed with a 2.2 cm left lower lobe pulmonary nodule, confirmed as adenocarcinoma. The imaging studies, including PET-CT, show no evidence of metastatic disease, indicating a localized tumor. The AJCC staging indicates a T1N1M0 stage, suggesting a stage IB cancer. The treatment plan involves lobectomy, and if the tumor is stage I without nodal involvement, adjuvant chemotherapy is not required. Given the early stage and appropriate treatment, cancer-related mortality within 3 years is not expected. </think> <brief reasoning trace with explanation for answer selection> The patient has a T1N1M0 stage lung adenocarcinoma with no evidence of metastasis. The treatment plan includes lobectomy, and if the tumor is stage I without nodal involvement, adjuvant chemotherapy is not required. Given the early stage and appropriate treatment, cancer-related mortality within 3 years is not expected. | <answer>No</answer>

no radiology report: **[CORRECT]** <think> The timeline indicates a diagnosis of a malignant neoplasm of the bronchus and lung, staged as T1 N1 M0 according to the 7th edition of the AJCC. This stage suggests a localized cancer with regional lymph node involvement but no distant metastasis. The treatment appears to involve imaging and possibly chemotherapy or

other oncological interventions. Given the stage and typical prognosis for such cancers, patients often have a significant survival rate beyond three years with appropriate treatment. There is no explicit evidence of advanced disease or treatment failure within the provided timeline that would suggest imminent mortality within three years. </think> <brief reasoning trace with explanation for answer selection> The patient has a malignant neoplasm of the bronchus and lung, staged T1 N1 M0, indicating localized disease with regional lymph node involvement but no distant metastasis. The typical prognosis for such cancers, with appropriate treatment, often extends beyond three years. There is no explicit evidence of advanced disease or treatment failure suggesting imminent mortality within three years. | <answer>No</answer>

100 axial images (no timeline): [CORRECT] <brief reasoning trace with explanation for answer selection> | <answer></answer> The provided PATIENT_TIMELINE does not include any specific medical history, cancer evidence, imaging, pathology, or treatment details. Without explicit evidence regarding the presence of cancer, its stage, or treatment outcomes, it is not possible to determine the likelihood of cancer-related mortality within 3 years of treatment initiation. | <answer>No</answer>

Model: OctoMed/OctoMed-7B

middle image from each view: [CORRECT] <think>First, I need to determine if the patient has cancer-related mortality expected within 3 years of treatment initiation based on the provided timeline and medical data. The patient is a 61-year-old female diagnosed with left lower lobe adenocarcinoma of the lung (T1N0M0 stage). Key points from the timeline: 1. **Diagnosis and Staging**: - CT-guided FNA confirmed adenocarcinoma. - PET-CT showed a 2.2 cm nodule without nodal involvement or distant metastasis. - No evidence of metastatic disease on brain MRI. - No lymph node involvement noted. 2. **Treatment Plan**: - Planned lobectomy (as per tumor board discussion). - No indication of advanced disease requiring neoadjuvant therapy. - No mention of metastatic disease or high-risk features. 3. **Prognostic Factors**: - Tumor is T1N0M0, which is early stage. - No nodal or distant metastasis. - Patient is active and has no significant comorbidities that would preclude surgery. - No biomarkers indicating aggressive disease (e.g., EGFR, ALK status not mentioned). - No prior history of metastasis or recurrence. 4. **Surveillance and Follow-up**: - Nonspecific GGOs and small nodules noted but not concerning for metastasis. - Patient is undergoing staging workup but no evidence of advanced disease. 5. **Mortality Risk**: - For early-stage non-small cell lung cancer (NSCLC), 5-year survival is generally >60%. - Within 3 years, the risk of cancer-related mortality is low if the tumor is completely resected and no recurrence. - No evidence of aggressive features or high-risk factors in the provided data. Given the absence of metastatic disease, no nodal involvement, and early stage, the patient's prognosis is favorable. The treatment plan aligns with standard care for early-stage lung cancer. Therefore, there is no indication of cancer-related mortality expected within 3 years.</think> <answer>No</answer>

middle axial image: [CORRECT] <think>First, I need to determine if the patient has cancer-related mortality expected within 3 years of treatment initiation based on the provided timeline and medical records. The patient is a 61-year-old female diagnosed with left lower lobe adenocarcinoma of the lung. Key points from the timeline: - Diagnosis: 2.2 cm spiculated nodule in left lower lobe, biopsy confirmed adenocarcinoma. - Staging: PET-CT and CT show no nodal involvement or metastasis. No evidence of metastatic disease. - Treatment Plan: Lobectomy planned, likely stage I given no nodal involvement. - Comorbidities: History of DCIS, asthma, hypothyroidism, and other non-cancer conditions. - No mention of distant metastasis or high-risk features like large tumor size, positive nodes, or poor performance status. - The patient is active, with no significant weight loss or other symptoms suggesting advanced disease. - The tumor is localized, and treatment is surgical with possible adjuvant therapy depending on final pathology. Given the absence of metastatic disease, no high-risk features, and the tumor being localized (stage I), the prognosis is generally favorable. The patient's age and comorbidities do

not suggest a high risk of mortality within 3 years. The main concern is the potential for recurrence, but the question is about cancer-related mortality within 3 years. Therefore, based on the information, the answer is "No" because there is no evidence of advanced disease or factors indicating high mortality risk within 3 years.</think> <brief reasoning trace with explanation for answer selection | <answer>No</answer>

no image: [CORRECT] <think>First, I need to determine whether the patient's cancer-related mortality is expected within 3 years of treatment initiation based on the provided timeline and medical records. The key factors to consider include the cancer stage, tumor biology, treatment intent, completeness, surgical margins, nodal status, biomarkers, and any other relevant clinical data. Looking at the patient's history, she was diagnosed with a 2.2 cm left lower lobe adenocarcinoma of the lung. The PET-CT showed no evidence of metastasis, and the MRI brain also showed no metastatic disease. The tumor is described as T1 (based on imaging), which typically indicates a localized tumor without lymph node involvement. The biopsy confirmed adenocarcinoma with certain immunohistochemical markers (TTF-1 negative, BRST-2 negative, napsin A positive), which aligns with lung adenocarcinoma. The patient underwent a CT-guided FNA and core biopsy, which confirmed the diagnosis. The treatment plan includes lobectomy, as indicated by the tumor board discussion. The patient is scheduled for surgery, and the plan is to evaluate mediastinal nodes intraoperatively. There is no mention of lymph node involvement or distant metastasis at this stage. The patient's overall health is stable, with no significant comorbidities that would preclude surgery. She is active and has a good performance status. The presence of other conditions like asthma and hypothyroidism is noted but does not seem to impact her current treatment plan. Given that the tumor is localized (T1N0M0), the prognosis is generally favorable with appropriate surgical resection. The 5-year survival rate for stage I non-small cell lung cancer (NSCLC) is relatively high, often exceeding 60-70%. However, the question is about mortality within 3 years. For stage I NSCLC, the 3-year survival rate is approximately 70-80%, indicating that mortality within 3 years is not expected if the treatment is successful. There is no evidence of nodal involvement, distant metastasis, or other high-risk features that would suggest a poor prognosis. The patient is undergoing appropriate staging and treatment, and there are no indications of aggressive disease or complications that would lead to early mortality. Therefore, based on the available information, the patient's cancer-related mortality is not expected within 3 years of treatment initiation.</think> <brief reasoning trace with explanation for answer selection> | <answer>No</answer>

no radiology report: [INCORRECT] <think>First, I carefully examine the provided CT images and the associated timeline data to assess the patient's condition and treatment history. The images show axial CT scans of the chest and pelvis, with no clear evidence of metastatic disease or recurrence. The patient's timeline includes multiple visits and procedures, including imaging and oxygen therapy, but no indication of cancer progression or recurrence is evident. The patient's treatment appears to be stable, with no signs of complications or deterioration. Based on the available data, there is no evidence to suggest cancer-related mortality within 3 years of treatment initiation.</think> <answer>No</answer>

100 axial images (no timeline): [CORRECT] <think>To determine whether cancer-related mortality is expected within 3 years of treatment initiation, I must analyze the provided patient timeline. The timeline only includes the date of birth and ethnicity/race information, but no clinical details such as cancer diagnosis, stage, treatment type, or outcomes. Without this critical data, it is impossible to assess the risk of cancer-related mortality. The timeline lacks any evidence of cancer treatment initiation, progression, or survival data. Therefore, I cannot conclude whether cancer-related mortality is expected within 3 years. The answer must be based solely on the available information, which is insufficient to make a definitive judgment.</think> <answer>No</answer>

Model: Qwen/Qwen3-VL-8B-Instruct

middle image from each view: **[CORRECT]** The patient was diagnosed with stage I lung adenocarcinoma in April 2013. The PET-CT and CT scans confirmed a 2.2 cm left lower lobe nodule with no evidence of metastatic disease. The tumor board unanimously decided to proceed with a lobectomy in May 2013. The patient is described as extremely active and without significant comorbidities that would negatively impact prognosis. For stage I non-small cell lung cancer, the standard of care is surgical resection, and the 5-year survival rate is very high (often over 80%). Given the early stage, complete resection, and absence of metastatic disease, cancer-related mortality within 3 years of treatment initiation is not expected. No | No

middle axial image: **[CORRECT]** The patient was diagnosed with stage I lung adenocarcinoma (T1N0M0) in 2013, based on imaging and biopsy results. The tumor was localized to the left lower lobe, with no evidence of nodal or distant metastasis. The treatment plan, as discussed in the tumor board on 05/22/2013, was to proceed with lobectomy. For a stage I lung cancer, adjuvant chemotherapy is not indicated, and the patient was deemed to be a good surgical candidate. The patient's overall health, including her activity level and absence of significant comorbidities (aside from asthma and osteopenia), supports a favorable prognosis. The timeline indicates that treatment initiation (lobectomy) occurred shortly after diagnosis, and with stage I disease, the 5-year survival rate is typically over 90%. Therefore, cancer-related mortality within 3 years of treatment initiation is not expected. No | No

no image: **[CORRECT]** <brief reasoning trace with explanation for answer selection> | <answer></answer> The patient was diagnosed with stage I lung adenocarcinoma (T1N0M0) based on imaging and biopsy results, with no evidence of metastasis. The tumor was localized and resectable, and the tumor board unanimously decided to proceed with lobectomy. The patient is otherwise healthy, with no significant comorbidities or symptoms, and is highly active. Stage I lung cancer has an excellent prognosis with surgical resection, and adjuvant chemotherapy is not indicated for stage I. Given the absence of metastatic disease, the patient’s good performance status, and the curative intent of surgery, cancer-related mortality within 3 years is not expected. <answer>No</answer>

no radiology report: **[INCORRECT]** The patient's medical timeline indicates a diagnosis of malignant neoplasm of the bronchus and lung (ICD9CM/162.9) in April 2013, with a clinical staging of cT1N1M0 (AJCC 7th Edition) on May 2, 2013. This is a stage IIIA lung cancer. The timeline includes imaging (CT chest, PET-CT) and a chest tube placement, suggesting an invasive procedure, likely for tumor resection or complication management. The patient's age at diagnosis (62 years old in 2013) and the stage of disease are significant prognostic factors. Stage IIIA non-small cell lung cancer has a 5-year survival rate of approximately 20-30% with treatment. Given the stage, the patient's age, and the absence of any evidence of treatment completion or disease control in the provided timeline, cancer-related mortality within 3 years of treatment initiation is a reasonable expectation. <brief reasoning trace with explanation for answer selection> | <answer></answer> The patient was diagnosed with stage IIIA lung cancer (cT1N1M0) in 2013. Stage IIIA non-small cell lung cancer has a 5-year survival rate of approximately 20-30% with treatment. Given the stage, the patient's age, and the absence of evidence of treatment completion or disease control in the provided timeline, cancer-related mortality within 3 years of treatment initiation is a reasonable expectation. | Yes

100 axial images (no timeline): **[CORRECT]** The provided PATIENT_TIMELINE contains no information regarding any cancer diagnosis, treatment, or related clinical findings. There are no entries describing tumors, imaging results, pathology reports, or any oncological history. Without any evidence of cancer or its progression, it is impossible to determine cancer-related mortality risk. <brief reasoning trace with explanation for answer selection> | <answer>No</answer>

Model: google/medgemma-1.5-4b-it

middle image from each view: **[CORRECT]** <unused94>thought The user wants me to determine if cancer-related mortality is expected within 3 years based on the provided patient timeline. 1. **Identify the core question:** Is cancer-related mortality expected within 3 years? 2. **Scan the timeline for cancer diagnosis and treatment:** * April 2013: Diagnosis of adenocarcinoma of the lung (left lower lobe). * May 2013: CT-guided FNA and core biopsy confirms adenocarcinoma. * May 15, 2013: MRI brain shows no evidence of metastatic disease. * May 16, 2013: PET-CT shows a 2.2 cm left lower lobe pulmonary nodule (consistent with the biopsy finding) but no evidence of metastasis. * May 2013: Tumor board discussion recommends lobectomy. * May 2013: Patient undergoes lobectomy. * May 2013: Pathology confirms adenocarcinoma. 3. **Assess the stage and treatment:** * The tumor is described as T1 (based on the clinical notes and staging codes). * The patient underwent surgery (lobectomy). * There is no mention of adjuvant chemotherapy or radiation therapy. * There is no mention of recurrence or metastasis. 4. **Evaluate the risk of mortality:** * T1 lung cancer, especially after surgery, generally has a very low risk of mortality within 3 years. The 5-year survival rate for T1 lung cancer is typically very high (often >90%). * The patient has no evidence of metastatic disease. * The patient is relatively young (61 years old). 5. **Formulate the answer:** Based on the diagnosis of T1 lung cancer and successful surgical resection without evidence of metastasis, the risk of cancer-related mortality within 3 years is very low. 6. **Select the correct option:** "No". 7. **Construct the reasoning:** The patient was diagnosed with T1 lung adenocarcinoma in April 2013. She underwent lobectomy in May 2013. Subsequent imaging (MRI brain, PET-CT) showed no evidence of metastatic disease. T1 lung cancer, especially after surgical resection, has a very low risk of mortality within 3 years. Therefore, cancer-related mortality is not expected within 3 years.<unused95><brief reasoning trace with explanation for answer selection>The patient was diagnosed with T1 lung adenocarcinoma in April 2013. She underwent lobectomy in May 2013. Subsequent imaging (MRI brain, PET-CT) showed no evidence of metastatic disease. T1 lung cancer, especially after surgical resection, has a very low risk of mortality within 3 years. Therefore, cancer-related mortality is not expected within 3 years. <answer>No</answer>

middle axial image: **[CORRECT]** <brief reasoning trace with explanation for answer selection> | <answer></answer> 1. **Analyze the Request:** The user wants me to determine if cancer-related mortality is expected within 3 years based on the provided patient timeline and select the correct option ("Yes" or "No"). 2. **Review the Timeline:** I need to scan the timeline for any evidence of cancer diagnosis, treatment, staging, prognosis, or mortality. * **Diagnosis:** The timeline shows a diagnosis of adenocarcinoma of the lung (ICD9CM/162.9, STANFORD_NOTE/ip-letter, STANFORD_NOTE/SR-). The biopsy was performed on 05/04/2013. * **Staging:** The timeline includes PET-CT (05/16/2013) and CT chest (04/27/2013). The PET-CT shows a 2.2 cm left lower lobe pulmonary nodule with CD max 4.9. The CT chest shows a 2 x 2.1-cm masslike opacity with spiculated margins in the left lower lobe. The report mentions "no obvious nodal involvement by size criteria or PET avidity" and "nonspecific GGOs and very small nodules." The report also mentions endometrial FDG uptake and bilateral ovarian cysts, which are noted as potentially incidental. * **Treatment:** The timeline shows a CT-guided FNA and core biopsy on 05/04/2013. It also shows a chest tube placement on 05/03/2013 and removal on 06/04/2013. The patient is on menopausal hormone therapy. * **Prognosis/Mortality:** The timeline does not explicitly state a prognosis or expected mortality. However, the diagnosis is lung cancer, which is a serious condition. The staging information (T1N0M0 based on the report) suggests a relatively early stage. While early-stage lung cancer has a good prognosis, it is still cancer. The timeline does not provide any information about the patient's overall health, comorbidities, or response to treatment. 3. **Evaluate the Question:** The question asks about *expected* cancer-related mortality within 3 years. This implies a prediction based on the available data. 4. **Synthesize Findings:** The patient has been diagnosed with lung cancer (adenocarcinoma). The staging appears to be

T1N0M0 based on the report. While T1N0M0 lung cancer has a relatively good prognosis, it is still a cancer diagnosis. The timeline does not provide enough information to make a definitive prediction about mortality within 3 years. The report mentions "no obvious nodal involvement" and "no evidence of metastasis" on the PET-CT, which is positive. The report also mentions incidental findings (endometrial FDG uptake, ovarian cysts) that may or may not be related to the cancer. Without more information (e.g., specific tumor biology, patient's overall health, treatment plan details, follow-up imaging), it is impossible to definitively say whether cancer-related mortality is expected within 3 years. The timeline provides a diagnosis but lacks the necessary details for a prognosis. 5. **Select the Answer:** Since the timeline provides a diagnosis of cancer but lacks sufficient information to predict mortality within 3 years, the most appropriate answer is "No". The timeline does not contain evidence *supporting* the expectation of cancer-related mortality within 3 years. It only provides the diagnosis. 6. **Format the Output:** Follow the required format: `<brief reasoning trace with explanation for answer selection> | <answer></answer>`. <brief reasoning trace with explanation for answer selection> | <answer></answer> The patient timeline includes a diagnosis of lung adenocarcinoma (ICD9CM/162.9, STANFORD_NOTE/ip-letter, STANFORD_NOTE/SR-). The staging report suggests a T1N0M0 classification. While T1N0M0 lung cancer generally has a favorable prognosis, the timeline does not provide sufficient information to predict cancer-related mortality within 3 years. There is no mention of specific tumor biology, patient comorbidities, treatment details, or follow-up findings that would allow for a prognosis. Therefore, based solely on the provided timeline, it is not possible to definitively state that cancer-related mortality is expected within 3 years. | No

no image: **[INCORRECT]** <brief reasoning trace with explanation for answer selection> | <answer></answer> The patient has a history of lung adenocarcinoma diagnosed in April 2013. The patient underwent a PET-CT scan in May 2013, which showed a 2.2 cm left lower lobe pulmonary nodule with an SUVmax of 4.9, consistent with malignancy. The PET-CT also showed no evidence of metastatic disease. The patient subsequently underwent a CT-guided biopsy, confirming the diagnosis of adenocarcinoma. The patient has also had a history of DCIS, which is a precursor to breast cancer, but the breast cancer is in remission. The patient has a history of asthma, but no recent hospitalizations or ER visits related to it. The patient has been on menopausal hormone therapy. The patient has a history of smoking, but quit 11-12 years ago. The patient has a history of Crohn's disease, which is reportedly in remission. The patient has a history of hypothyroidism and allergies. The patient has had a chest tube placed and removed. The patient has had a brain MRI and a pulmonary function test (PFT) with DLCO. The patient's clinical presentation, imaging findings (lung nodule, no metastasis), and biopsy results are consistent with a primary lung cancer diagnosis. The patient's history of DCIS is noted but does not change the current diagnosis of lung cancer. The patient's history of asthma and menopausal hormone therapy are relevant comorbidities but do not alter the assessment of cancer risk or prognosis based on the provided information. The patient's history of smoking, although remote, is a significant risk factor for lung cancer. The patient's history of Crohn's disease is not directly related to the current lung cancer diagnosis. The patient's history of hypothyroidism and allergies are also not directly related. The patient's history of DCIS is a risk factor for breast cancer, but the patient is currently in remission from this. The patient's history of a chest tube placement is related to a previous medical issue, not the current lung cancer. The patient's history of a brain MRI and PFT are related to the current workup for lung cancer. The patient's history of being on menopausal hormone therapy is relevant for potential treatment planning and side effects, but does not directly impact the likelihood of cancer mortality based on the provided evidence. The patient's history of asthma is relevant for potential treatment side effects (e.g., bronchospasm). The patient's history of Crohn's disease is not directly related to the current lung cancer diagnosis. The patient's history of hypothyroidism and allergies are not directly related to the current lung cancer diagnosis. The patient's history of DCIS is a risk factor for breast cancer, but the patient is currently in remission from this. The

patient's history of a chest tube placement is related to a previous medical issue, not the current lung cancer. The patient's history of a brain MRI and PFT are related to the current workup for lung cancer. The patient's history of being on menopausal hormone therapy is relevant for potential treatment planning and side effects, but does not directly impact the likelihood of cancer mortality based on the provided evidence. The patient's history of asthma is relevant for potential treatment side effects (e.g., bronchospasm). The patient's history of Crohn's disease is not directly related to the current lung cancer diagnosis. The patient's history of hypothyroidism and allergies are not directly related to the current lung cancer diagnosis. The patient's history of DCIS is a risk factor for breast cancer, but the patient is currently in remission from this. The patient's history of a chest tube placement is related to a previous medical issue, not the current lung cancer. The patient's history of a brain MRI and PFT are related to the current workup for lung cancer. The patient's history of being on menopausal hormone therapy is relevant for potential treatment planning and side effects, but does not directly impact the likelihood of cancer mortality based on the provided evidence. The patient's history of asthma is relevant for potential treatment side effects (e.g., bronchospasm). The patient's history of Crohn's disease is not directly related to the current lung cancer diagnosis. The patient's history of hypothyroidism and allergies are not directly related to the current lung cancer diagnosis. The patient's history of DCIS is a risk factor for breast cancer, but the patient is currently in remission from this. The patient's history of a chest tube placement is related to a previous medical issue, not the current lung cancer. The patient's history of a brain MRI and PFT are related to the current workup for lung cancer. The patient's history of being on menopausal hormone therapy is relevant for potential treatment planning and side effects, but does not directly impact the likelihood of cancer mortality based on the provided evidence. The patient's history of asthma is relevant for

no radiology report: **[INCORRECT]** The patient has a history of malignant neoplasm of bronchus and lung, unspecified, diagnosed in 2013. The patient has undergone multiple imaging studies including CT chest and PET scan, as well as a chest tube placement and removal. The patient has also had spirometry and bronchodilation responsiveness testing. The patient's current status is not explicitly stated, but the presence of a malignancy, even if treated, carries a risk of recurrence or progression. The patient's BMI is 26.5, which is overweight. The patient has a history of asthma. The patient has had multiple procedures and tests, including chest tube placement and removal, spirometry, and bronchodilation responsiveness testing. The patient has also had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan.

The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging studies including CT chest and PET scan. The patient has had multiple visits for case management. The patient has had multiple imaging

100 axial images (no timeline): **[INCORRECT]** FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |

```
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 |
CT_Chest_Abdomen_Pelvis_
```

Model: google/medgemma-4b-it

middle image from each view: **[CORRECT]** No

middle axial image: **[CORRECT]** No

no image: **[CORRECT]** No

no radiology report: **[CORRECT]** No

100 axial images (no timeline): **[CORRECT]** The images show a well-defined, homogeneous mass within the breast tissue. The presence of a mass and the lack of any mention of metastasis or other concerning features suggests a localized, potentially treatable cancer. Given the absence of information about the stage, grade, or treatment plan, it is impossible to determine the expected cancer-related mortality within 3 years. No

Subtask: died_of_cancer_4_yr

Question:

Based on the provided medical history and cancer evidence, is cancer-related mortality expected within 4 years of treatment initiation?

Correct Answer: No

Model: OpenGVLab/InternVL3_5-8B

middle image from each view: **[CORRECT]** <think> The patient was diagnosed with a T1N1M0 lung adenocarcinoma, which is a stage IB cancer. The treatment plan included lobectomy, and if the tumor is stage IB or II, adjuvant chemotherapy would be needed. The patient's overall health appears stable, with no significant comorbidities that would affect treatment outcomes. Given the stage and treatment plan, the expected survival rate for a 4-year period post-treatment initiation is generally favorable, suggesting that cancer-related mortality is not expected within this timeframe. </think> <brief reasoning trace with explanation for answer selection> The patient has a stage IB lung adenocarcinoma (T1N1M0) and is planned for lobectomy with possible adjuvant chemotherapy if needed. The staging and treatment plan suggest a favorable prognosis, indicating that cancer-related mortality is not expected within 4 years. | <answer>No</answer>

middle axial image: **[CORRECT]** <think> The patient has been diagnosed with a T1N1M0 lung adenocarcinoma, which is a stage IB cancer. According to the AJCC 7th edition staging, stage IB tumors have a 5-year survival rate of approximately 70-80%. The patient is planned for lobectomy, which is the standard treatment for stage IB lung cancer. The absence of metastasis (M0) and the localized nature of the tumor (T1N1) suggest a favorable prognosis. The patient's overall health appears stable, with no significant comorbidities that would adversely affect treatment outcomes. Given the stage and treatment plan, cancer-related mortality within 4 years of treatment initiation is not expected. </think> <brief reasoning trace with explanation for answer selection> The patient has a stage IB lung adenocarcinoma (T1N1M0) with no evidence of metastasis. The treatment plan includes lobectomy, which is effective for localized tumors. The 5-year survival rate for stage IB is high, and there are no significant comorbidities affecting prognosis. | <answer>No</answer>

no image: **[CORRECT]** <think> The patient is a 61-year-old female diagnosed with a T1N1M0 stage lung adenocarcinoma. The imaging studies, including PET-CT, show a 2.2 cm left lower lobe pulmonary nodule with no evidence of metastatic disease. The patient underwent a lobectomy, and the decision to proceed with surgery was made after tumor board discussion. Given the stage I or IB classification, the patient is unlikely to require adjuvant chemotherapy if there is no nodal involvement. The patient's overall health status appears stable, with no significant comorbidities that would adversely affect prognosis. The absence of metastatic disease and the localized nature of the tumor suggest a favorable prognosis, reducing the likelihood of cancer-related mortality within 4 years of treatment initiation. </think> <brief reasoning trace with explanation for answer selection> The patient has a T1N1M0 stage lung adenocarcinoma with no evidence of metastatic disease. The tumor is localized, and the patient is expected to undergo lobectomy without the need for adjuvant chemotherapy if there is no nodal involvement. The absence of metastasis and the localized nature of the tumor suggest a favorable prognosis, reducing the likelihood of cancer-related mortality within 4 years. | <answer>No</answer>

no radiology report: [INCORRECT] <think> The timeline indicates a diagnosis of a malignant neoplasm of the bronchus and lung, staged as T1 N1 M0, which is Stage IIIA according to the 7th AJCC edition. This stage suggests a localized but advanced cancer with regional lymph node involvement. The treatment plan likely involves a combination of surgery, chemotherapy, and/or radiation therapy. Given the stage and typical prognosis for such cancers, there is a significant risk of cancer-related mortality within 4 years without effective treatment. The presence of additional conditions like asthma and the patient's overall health metrics (BMI, blood pressure) might impact treatment outcomes, but the primary concern remains the advanced stage of the cancer. </think> <brief reasoning trace with explanation for answer selection> The patient has a Stage IIIA malignant neoplasm of the bronchus and lung (T1 N1 M0), which typically has a poorer prognosis and higher risk of mortality within 4 years. The advanced stage and regional lymph node involvement suggest a challenging treatment course, increasing the likelihood of cancer-related mortality. | <answer>Yes</answer>

100 axial images (no timeline): [CORRECT] <brief reasoning trace with explanation for answer selection> | <answer></answer> The provided PATIENT_TIMELINE does not include any specific medical history, cancer evidence, imaging, pathology, or treatment details. Without explicit evidence regarding the presence of cancer, its stage, or treatment outcomes, it is not possible to determine the expected cancer-related mortality within 4 years of treatment initiation. | <answer>No</answer>

Model: OctoMed/OctoMed-7B

middle image from each view: [CORRECT] <think>First, I need to determine whether the patient's cancer-related mortality is expected within 4 years of treatment initiation based on the provided medical history and imaging findings. The patient is a 61-year-old female diagnosed with left lower lobe adenocarcinoma of the lung. The tumor is T1N0M0 (no nodal involvement or metastasis evident on imaging). She underwent a PET-CT which showed no metastatic disease, and the biopsy confirmed adenocarcinoma. She has a history of DCIS treated with lumpectomy and tamoxifen, and no recent recurrence. She is currently on menopausal hormone therapy. The key factors to consider for prognosis and mortality risk include: - Tumor stage: T1N0M0 suggests early-stage lung cancer. - No evidence of nodal involvement or distant metastasis on imaging. - She is undergoing lobectomy as planned, which is standard for early-stage lung cancer. - No mention of high-risk features such as positive margins, lymphovascular invasion, or poor differentiation. - She has no significant comorbidities that would drastically affect survival. - The patient is active and has no symptoms like weight loss or night sweats, which could indicate advanced disease. Given the early stage and absence of metastasis, the prognosis is generally favorable. The 5-year survival rate for stage I lung cancer is relatively high, often exceeding 60-70%. Without evidence of recurrence or metastasis, the likelihood of cancer-related mortality within 4 years is low. Therefore, based on the provided data, there is no indication that cancer-related mortality is expected within 4 years.</think> <answer>No</answer>

middle axial image: [CORRECT] <think>First, I need to determine whether the patient's cancer-related mortality is expected within 4 years of treatment initiation based on the provided timeline and medical records. The patient is a 61-year-old female diagnosed with left lower lobe adenocarcinoma of the lung. The tumor is T1N0M0 (no nodal involvement or metastasis evident on imaging). She underwent a PET-CT which showed no metastatic disease, and the biopsy confirmed adenocarcinoma. She has a history of DCIS treated with lumpectomy and tamoxifen, and currently is on menopausal hormone therapy. Key factors to consider for prognosis and mortality risk: - Tumor stage: T1N0M0, which is early stage. - No evidence of nodal involvement or distant metastasis. - She is undergoing lobectomy as planned, which is standard for early-stage lung cancer. - No mention of high-risk features such as positive margins, lymphovascular invasion, or poor differentiation. - She has comorbidities including asthma,

hypothyroidism, and a history of smoking, but these do not directly impact cancer prognosis. - The patient is active and has no significant symptoms like weight loss or night sweats, which would suggest advanced disease. - The PET-CT showed no FDG-avid lymph nodes or distant metastases. - The FRAX score for osteoporosis and BMD are within normal limits, indicating no significant bone metastasis risk. - The patient has been followed for ovarian cysts and endometrial FDG uptake, but these are likely unrelated to the lung cancer and are being monitored separately. Given the early stage (T1N0M0) and absence of high-risk features, the prognosis is generally favorable. The standard treatment for T1N0M0 lung adenocarcinoma is lobectomy, and adjuvant therapy is not indicated unless there are high-risk features. The patient is scheduled for surgery, and there is no indication of recurrence or metastasis at this time. Therefore, based on the available data, there is no evidence to suggest cancer-related mortality within 4 years. The patient's cancer appears to be localized and treatable with surgery, and no high-risk factors are noted that would significantly increase mortality risk.</think> <answer>No</answer>

no image: **[CORRECT]** <think>First, I need to determine whether the patient's cancer-related mortality is expected within 4 years of treatment initiation based on the provided timeline and medical records. The key factors to consider include the cancer stage, tumor biology, treatment details, and any available prognostic indicators. Looking at the patient's history, she was diagnosed with a 2.2 cm left lower lobe adenocarcinoma of the lung. The tumor is T1 (based on imaging), and there is no evidence of nodal involvement or metastasis on PET-CT or brain MRI. This suggests an early-stage lung cancer (likely stage I). The patient underwent a CT-guided FNA and core biopsy, confirming adenocarcinoma. The treatment plan includes lobectomy, which is standard for early-stage non-small cell lung cancer (NSCLC). The patient's performance status is good, as she is active and able to exercise. There are no significant comorbidities that would contraindicate surgery. The tumor markers and IHC (TTF-1 negative, BRST-2 negative, napsin A positive) are consistent with adenocarcinoma but do not indicate aggressive biology. The patient has a history of DCIS and is on hormone therapy, but this does not directly affect lung cancer prognosis. The presence of small nodules and ground-glass opacities is noted but not indicative of metastatic disease. The patient is scheduled for surgery and will undergo mediastinal node sampling, which is appropriate for staging. Given the early stage, absence of nodal or metastatic disease, and planned curative surgery, the prognosis is favorable. The 5-year survival rate for stage I lung adenocarcinoma is approximately 60-80%, indicating that mortality within 4 years is unlikely. However, the question is specifically about mortality within 4 years. Since the patient is undergoing definitive treatment and has no high-risk features, the likelihood of cancer-related mortality within 4 years is low. Therefore, based on the provided information, the answer is "No."</think> <brief reasoning trace with explanation for answer selection> | <answer>No</answer>

no radiology report: **[INCORRECT]** <think>First, I carefully examine the provided CT images and the associated timeline data to assess the patient's condition and treatment history. The images show axial CT scans of the chest and pelvis, with no clear evidence of metastatic disease or recurrence. The patient's timeline includes multiple visits and procedures, including imaging and oxygen therapy, but no indication of cancer progression or recurrence is evident. The patient's treatment appears to be stable, with no signs of complications or deterioration. Based on the available data, there is no evidence to suggest cancer-related mortality within 4 years of treatment initiation.</think> <answer>No</answer>

100 axial images (no timeline): **[CORRECT]** <think>To determine whether cancer-related mortality is expected within 4 years of treatment initiation, I must analyze the provided patient timeline and any relevant clinical data. However, the timeline provided only includes the date of birth and ethnicity/race, with no mention of cancer diagnosis, treatment details, or outcomes. There is no evidence of cancer-related events, treatment initiation, or mortality data. Without specific clinical information such as tumor stage, treatment type, or survival data, it is impossible to assess cancer-related mortality risk. Therefore, based solely on the provided timeline, there

is no evidence to suggest cancer-related mortality within 4 years of treatment initiation.</think> <answer>No</answer>

Model: Qwen/Qwen3-VL-8B-Instruct

middle image from each view: **[CORRECT]** The patient was diagnosed with stage I lung adenocarcinoma in April 2013. The timeline shows that a tumor board meeting occurred on May 22, 2013, and the unanimous decision was to proceed with a lobectomy. The patient's clinical status at the time of diagnosis was described as "well-appearing" with no significant symptoms beyond anxiety. The imaging (PET-CT, MRI brain, CT chest) confirmed a localized tumor with no evidence of metastasis. The treatment plan was surgical resection, with adjuvant chemotherapy only if the tumor was found to be stage IB or II. The patient was actively engaged in her care and was described as extremely active. Based on the stage (I), the treatment plan (surgery), and the patient's good clinical status at diagnosis, cancer-related mortality is not expected within 4 years of treatment initiation. No | No

middle axial image: **[CORRECT]** The provided PATIENT_TIMELINE documents a diagnosis of stage I lung adenocarcinoma (T1N0M0) in a 61-year-old female, confirmed by biopsy and staging imaging (PET-CT, MRI brain, CT chest). The tumor is localized to the left lower lobe with no evidence of metastasis. The treatment plan, as discussed at tumor board on 05/22/2013, is lobectomy. The note explicitly states: "If she is simply a stage I tumor without any nodal involvement, she will not need adjuvant chemotherapy." The patient is described as "extremely active" and "able to do the StairMaster for 20 minutes," indicating good functional status. There is no evidence of disease progression or recurrence in the timeline. Given the early stage (I), localized disease, and planned curative surgery without adjuvant chemotherapy, cancer-related mortality is not expected within 4 years of treatment initiation. No <answer>No</answer>

no image: **[CORRECT]** <brief reasoning trace with explanation for answer selection> | <answer></answer> The patient was diagnosed with stage I lung adenocarcinoma (T1N0M0) based on imaging and biopsy results, with no evidence of metastasis. The tumor was localized and resectable, and the tumor board unanimously decided to proceed with lobectomy. The patient is otherwise healthy, with no significant comorbidities or performance status limitations. Stage I lung cancer has a very favorable prognosis, with 5-year survival rates exceeding 80% for patients undergoing curative-intent surgery. Given the absence of metastatic disease, the localized nature of the tumor, and the planned curative surgical intervention, cancer-related mortality within 4 years is not expected. <answer>No</answer>

no radiology report: **[INCORRECT]** The patient's medical timeline indicates a diagnosis of malignant neoplasm of the bronchus and lung (ICD9CM/162.9) in April 2013, with a clinical staging of cT1N1M0 (AJCC 7th Edition) on May 2, 2013. This is a stage IIIA lung cancer. The timeline includes imaging (CT chest, PET-CT) and a chest tube placement, suggesting an invasive procedure, likely for a lung mass or complication. The patient's age at diagnosis (62 years old in 2013) and the stage of disease are significant prognostic factors. Stage IIIA non-small cell lung cancer has a 5-year survival rate of approximately 20-30% with treatment, and the prognosis is generally poor for patients with advanced disease. The timeline does not show evidence of treatment completion or disease control beyond the initial diagnosis and staging. Given the stage, age, and lack of evidence of successful treatment or remission, cancer-related mortality within 4 years of treatment initiation is highly likely. <brief reasoning trace with explanation for answer selection> | <answer> The patient was diagnosed with stage IIIA lung cancer in 2013. Stage IIIA non-small cell lung cancer has a 5-year survival rate of approximately 20-30% with treatment, and the prognosis is generally poor for patients with advanced disease. The timeline does not show evidence of successful treatment or remission. Therefore, cancer-related mortality within 4 years of treatment initiation is expected. <answer>

100 axial images (no timeline): [CORRECT] The provided PATIENT_TIMELINE contains no information regarding any cancer diagnosis, treatment, or related clinical findings. There are no entries describing tumors, imaging results, pathology reports, or any oncological events. Without any evidence of cancer or its progression, it is impossible to determine cancer-related mortality risk. <brief reasoning trace with explanation for answer selection> | <answer>No</answer>

Model: google/medgemma-1.5-4b-it

middle image from each view: [CORRECT] <unused94>thought The user wants me to determine if cancer-related mortality is expected within 4 years based on the provided patient timeline. 1. **Identify the core question:** Is cancer-related mortality expected within 4 years? 2. **Scan the timeline for cancer diagnosis and treatment:** * April 2013: Diagnosis of adenocarcinoma of the lung (left lower lobe). * May 2013: CT-guided FNA and core biopsy confirms adenocarcinoma. * May 15, 2013: MRI brain shows no evidence of metastatic disease. * May 16, 2013: PET-CT shows a 2.2 cm left lower lobe pulmonary nodule (consistent with the biopsy finding) but no evidence of metastasis. * May 2013: Tumor board discussion recommends lobectomy. * May 2013: Patient undergoes lobectomy. * May 2013: Pathology confirms adenocarcinoma. 3. **Assess the stage and treatment:** * The tumor is described as T1 (based on the AJCC staging system, which is standard in oncology). * The patient underwent surgery (lobectomy). * There is no mention of adjuvant therapy (chemotherapy, radiation) or recurrence. 4. **Evaluate the prognosis for T1 lung cancer:** * T1 lung cancer is considered early-stage. * The 5-year survival rate for T1 lung cancer is generally high, often exceeding 90-95%, especially when treated surgically. * The patient has completed surgical treatment. 5. **Formulate the answer:** Based on the diagnosis of T1 lung cancer and completion of surgical treatment, the prognosis is generally very good, and cancer-related mortality within 4 years is not expected. 6. **Select the correct option:** "No". 7. **Construct the reasoning:** The patient was diagnosed with T1 lung cancer, which is an early stage. She underwent surgical resection (lobectomy). The 5-year survival rate for T1 lung cancer is high. There is no evidence of recurrence or metastasis. Therefore, cancer-related mortality within 4 years is not expected.<unused95><brief reasoning trace with explanation for answer selection> The patient was diagnosed with T1 lung cancer, which is considered an early stage. She underwent surgical resection (lobectomy). The 5-year survival rate for T1 lung cancer is generally high, often exceeding 90-95%. There is no evidence of recurrence or metastasis in the provided timeline. Therefore, cancer-related mortality within 4 years is not expected. | <answer>No</answer>

middle axial image: [CORRECT] <unused94>thought The user wants me to determine if cancer-related mortality is expected within 4 years based on the provided patient timeline. 1. **Identify the core question:** Is cancer-related mortality expected within 4 years? 2. **Scan the timeline for cancer diagnosis and treatment:** * April 2013: Diagnosis of adenocarcinoma of the lung (left lower lobe). * May 2013: CT-guided FNA and core biopsy confirms adenocarcinoma. * May 15, 2013: MRI brain shows no evidence of metastatic disease. * May 16, 2013: PET-CT shows a 2.2 cm left lower lobe pulmonary nodule (consistent with the biopsy finding) but no evidence of metastasis. * May 2013: Tumor board discussion recommends lobectomy. * May 2013: Patient undergoes lobectomy. 3. **Assess the stage and prognosis:** * The tumor is T1 (based on the AJCC 7th edition staging system, which is likely used in this context). * There is no evidence of nodal involvement (N0) or distant metastasis (M0) based on the PET-CT and MRI brain. * The patient is stage I. 4. **Consider factors influencing mortality:** * **Stage:** Stage I lung cancer has a very high cure rate, especially with surgery. * **Treatment:** The patient underwent surgery (lobectomy), which is the standard curative treatment for early-stage lung cancer. * **Prognosis:** For stage I lung cancer, the 5-year survival rate is typically >80-90%. This means that death from the cancer is highly unlikely within 4 years. 5. **Formulate the answer:** Based on the diagnosis of stage I lung cancer and successful

surgical treatment, cancer-related mortality within 4 years is not expected. 6. **Select the correct option:** "No". 7. **Construct the reasoning:** The patient was diagnosed with stage I lung cancer (T1N0M0) in April 2013. She underwent a lobectomy in May 2013. Stage I lung cancer has a very high cure rate, with 5-year survival rates typically exceeding 80-90%. Therefore, cancer-related mortality within 4 years is not expected.<unused95><brief reasoning trace with explanation for answer selection>The patient was diagnosed with stage I lung cancer (T1N0M0) in April 2013. She underwent a lobectomy in May 2013. Stage I lung cancer has a very high cure rate, with 5-year survival rates typically exceeding 80-90%. Therefore, cancer-related mortality within 4 years is not expected. <answer>No</answer>

no image: **[INCORRECT]** <brief reasoning trace with explanation for answer selection> | <answer></answer> The patient has a history of lung adenocarcinoma diagnosed in April 2013. The patient underwent a PET-CT scan in May 2013, which showed a 2.2 cm left lower lobe pulmonary nodule with an SUVmax of 4.9, consistent with malignancy. The PET-CT also showed no evidence of metastatic disease. The patient subsequently underwent a CT-guided biopsy, confirming the diagnosis of adenocarcinoma. The patient has also had a history of DCIS, which is a precursor to breast cancer, but the breast cancer is in remission. The patient has a history of asthma, but no recent hospitalizations or ER visits related to it. The patient has been on menopausal hormone therapy. The patient has a history of smoking, but quit 11-12 years ago. The patient has a history of Crohn's disease, which is reportedly in remission. The patient has a history of hypothyroidism and allergies. The patient has had a chest tube placed and removed. The patient has had a brain MRI and a pulmonary function test (PFT) with DLCO. The patient's clinical presentation, imaging findings (lung nodule, no metastasis), and biopsy results are consistent with a primary lung cancer diagnosis. The patient's history of DCIS is noted but does not change the current diagnosis of lung cancer. The patient's history of asthma and menopausal hormone therapy are relevant but do not alter the assessment of the lung cancer. The patient's history of smoking is a significant risk factor for lung cancer. The patient's history of Crohn's disease is not directly related to the lung cancer. The patient's history of hypothyroidism and allergies are not directly related to the lung cancer. The patient's history of DCIS is a separate condition. The patient's history of chest tube placement and removal is related to a previous procedure, not the current lung cancer. The patient's history of brain MRI and PFT with DLCO are related to the evaluation of the lung cancer and potential complications or comorbidities. The patient's history of smoking is a major risk factor for lung cancer. The patient's history of DCIS is a separate condition. The patient's history of Crohn's disease is not directly related to the lung cancer. The patient's history of hypothyroidism and allergies are not directly related to the lung cancer. The patient's history of chest tube placement and removal is related to a previous procedure, not the current lung cancer. The patient's history of brain MRI and PFT with DLCO are related to the evaluation of the lung cancer and potential complications or comorbidities. The patient's history of smoking is a major risk factor for lung cancer. The patient's history of DCIS is a separate condition. The patient's history of Crohn's disease is not directly related to the lung cancer. The patient's history of hypothyroidism and allergies are not directly related to the lung cancer. The patient's history of chest tube placement and removal is related to a previous procedure, not the current lung cancer. The patient's history of brain MRI and PFT with DLCO are related to the evaluation of the lung cancer and potential complications or comorbidities. The patient's history of smoking is a major risk factor for lung cancer. The patient's history of DCIS is a separate condition. The patient's history of Crohn's disease is not directly related to the lung cancer. The patient's history of hypothyroidism and allergies are not

directly related to the lung cancer. The patient's history of chest tube placement and removal is related to a previous procedure, not the current lung cancer. The patient's history of brain MRI and PFT with DLCO are related to the evaluation of the lung cancer and potential complications or comorbidities. The patient's history of smoking is a major risk factor for lung cancer. The patient's history of DCIS is a separate condition. The patient's history of Crohn's disease is not directly related to the lung cancer. The patient's history of hypothyroidism and allergies are not directly related to the lung cancer. The patient's history of chest tube placement and removal is related to a previous procedure, not the current lung cancer. The patient's history of brain MRI and PFT with DLCO are related to the evaluation of the lung cancer and

no radiology report: **[INCORRECT]** The patient has a history of malignant neoplasm of bronchus and lung, unspecified, diagnosed in 2013. The patient has undergone multiple imaging studies including CT chest and PET scan, as well as a chest tube placement and removal. The patient has also had spirometry and bronchodilation responsiveness testing. The patient's current status is not explicitly stated, but the presence of a malignancy, even if treated, carries a risk of recurrence or progression. The patient's BMI is 26.5, which is overweight. The patient has a history of asthma. The patient has had multiple procedures and tests, including chest tube placement and removal, spirometry, and bronchodilation responsiveness testing. The patient has also had multiple visits and imaging studies. The patient has had

multiple visits and imaging studies. The patient has had multiple visits and imaging studies.

100 axial images (no timeline): **[INCORRECT]** FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_1 FINDINGS_IMAGING_1 | 2019-03-18 00:00 | CT_Chest_Abdomen_Pelvis_

Model: google/medgemma-4b-it

middle image from each view: **[CORRECT]** No

middle axial image: **[CORRECT]** No

no image: **[CORRECT]** No

no radiology report: **[CORRECT]** No

100 axial images (no timeline): **[CORRECT]** The images show a well-defined, homogeneous mass within the breast tissue. The presence of a mass and the lack of any mention of metastasis or other concerning findings suggest a localized, potentially treatable cancer. Given the absence of information about the cancer stage, treatment, or follow-up, it is impossible to determine the expected cancer-related mortality within 4 years. No